NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 30

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 - 438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Holy Family Hospital	In accordance with application dated September 3, 1985 3. License number 12-13614-01 is amended in its entirety to read as follows:
2. 100 North River Road Des Plaines, IL 60016	4. Expiration date: January 31, 1991
	5. Docket or Reference No.: 030-01571

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2.0 curies of each byproduct material authorized in Subitem 6.B
C. Xenon-133	C. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	C. 1200 millicuries
D. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	D. Prepackaged kits	D. 3.0 millicuries of each byproduct material authorized in Subitem 6.D

1/1 M130 B4 FEB 5 - 1986

COPY 2

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 12-13614-01

Docket or Reference number 030-01571

Amendment No. 30

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
E. Iodine-131	E. Any iodide that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State regulations	E. 200 millicuries
F. Phosphorus-32	F. Any phosphate that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR Part 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State regulations	F. 25 millicuries
G. Iodine-125	G. Seeds (Licensed pursuant to Section 32.74 of 10 CFR Part 32 or equivalent Agreement State reguations)	G. 200 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 12-13614-01

Docket or Reference number 030-01571

Amendment No. 30

9. Authorized Use (cont'd)

C. Blood flow studies. Pulmonary function studies.

D. In vitro studies.

E. For treatment of polycythemia vera, leukemia and bone metastases.

F. For treatment of hyperthyroidism and cardiac dysfunction.

G. For interstitial treatment of carcinoma.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 100 North River Road, Des Plaines, Illinois.

11. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Mariano Marzo, M.D.	Groups I, II and III Iodine-131 for therapy Soluble phosphorus-32 for treatment of polycythemia vera, leukemia and bone metastases In vitro studies Xenon-133
Kenneth J. Maier, M.D.	Groups I, II and III Iodine-131 for therapy Soluble phosphorus-32 for treatment of polycythemia vera, leukemia and bone metastases In vitro studies Xenon-133
Kenneth D. Schmidt, M.D.	Groups I, II and III Xenon-133 Iodine-131 for therapy
Earl Suckow	In vitro studies
Jack D. Hansen, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism and cardiac dysfunction Xenon-133

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 12-13614-01

Docket or Reference number 030-01571

Amendment No. 30

Alvin Gross, M.D.	Iodine-125 seeds
Yoon Kim, M.D.	Iodine-125 seeds

12. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's Administrator and Radiation Safety Committee, and

    B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    C. Performs only those procedures which the physician is specifically authorized to perform pursuant to a license issued by the Nuclear Regulatory Commission.

    The licensee shall maintain for inspection by the Commission copies of the written permission specified in A. above and of the license(s) specified in B. and C. above for a period of 5 years from the date permission is granted under A. above.

13. Patients containing iodine-131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of gold-198) shall remain hospitalized until the residual activity is 30 millicuries or less.

14. The licensee shall record the results of dose calibrator constancy, accuracy, and geometrical variance tests and the results of daily area surveys in accordance with Appendices D and I of Regulatory Guide 10.8, October 1980.

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated September 3, 1985 and

    B. ALARA Program dated August 1, 1985.

For the U.S. Nuclear Regulatory Commission

Date FEB 5 - 1986

By Original Signed
R. J. Caniano
Materials Licensing Section, Region III

COPY